Space Motion Sickness & Readaptation Sickness: Prevention and Treatment
Also: space adaptation sickness · SAS · SMS · terrestrial readaptation motion sickness · promethazine in space
Gravity FieldsVestibular & SensorimotorGI & NutritionNeurological & CognitiveIn-flightEntry, Descent & LandingPostflight RecoveryParabolic / centrifugeSuborbitalLEO short-durationLEO long-durationLunar surfaceMars transit & surfaceClinicianOperator / SFPPublic
- Most first-time flyers (about 70–90%; NASA's brief cites ~73%) get space motion sickness in the first 2–3 days; it usually resolves within 72 hours as the brain adapts. ◆◆◆◆ High · F
- Terrestrial motion-sickness history does not reliably predict it; previous space motion sickness does. ◆◆◆◇ Moderate · F E
- Promethazine (25–50 mg; IM or suppository when vomiting) is NASA's treatment of choice; in Shuttle crews, 14 of 15 IM and 6 of 8 suppository users had relief within 1–2 hours, while oral scopolamine-dextroamphetamine prophylaxis left only 3 of 19 symptom-free. ◆◆◆◇ Moderate · F
- In early flight, promethazine has not been associated with the sedation seen on Earth, and pre-launch prophylaxis has not shown a clear benefit in NASA data. ◆◆◇◇ Low · F E
- Similar symptoms — plus vertigo and imbalance — recur after landing; treat symptomatically, prevent falls, and keep the patient off the road until balance returns. ◆◆◆◇ Moderate · F E
Proposed certainty (◆ High → ◇ Very low) and evidence-type tags: F flight · A analog · M model/animal · C computational · E expert/operational/standards. Grades are AI-proposed and pending medical reviewer confirmation. How we grade.
What to do
Preflight counseling (any clinician)
- Explain that motion sickness in space is expected, usually short-lived, and is not a sign of illness.
- Ask about previous spaceflight or parabolic-flight symptoms — the best predictor. Car-sickness history is not reliable [1].
- Review interacting drugs: other sedatives, anticholinergics, QT-prolonging drugs.
- Advise behavioral measures: limit head movements (pitch movements are most provocative), keep a consistent “up” orientation, fix gaze on a task, avoid strong odors and heat, stay hydrated [1].
- Defer to the operator’s flight surgeon for the in-flight medication plan.
In flight (as NASA practice describes it)
| Severity (NASA grading) | Features | Typical management |
|---|---|---|
| Mild (1) | A few mild symptoms, often provoked by head movements; up to one vomiting episode; resolves in 36–48 h | Behavioral measures, fluids |
| Moderate (2) | Persistent, waxing/waning malaise, anorexia; no more than 2 vomiting episodes; resolves in 72 h | Consider promethazine |
| Severe (3) | Pronounced malaise/lethargy, strong desire not to move the head; more than 2 vomiting episodes; may persist beyond 72 h | Promethazine IM or PR; fluids; check electrolytes |
Grading per OCHMO-MTB-004, citing Barratt et al. [1].
Operational rules worth knowing
NASA schedules spacewalks after 72 hours of flight to allow symptoms to resolve, and historically allowed time for recovery before entry; private medical conferences are frequent in the first week [1]. Vomiting inside a spacesuit helmet is a serious hazard — hence medical clearance before every EVA [V1 6006].
After landing (EM, primary care)
- Expect nausea, vertigo with head movement, imbalance and gait instability, especially after long flights. In 18 ISS crew, time to complete an obstacle course rose a median 48% after landing and recovered to 95% of baseline at about 15 days [5].
- Treat symptomatically (antiemetic, fluids); combine with orthostatic precautions — see Orthostatic intolerance.
- Falls precautions; no driving in the first week [6].
Red flags — think beyond motion sickness
- Symptoms beyond 72 hours, worsening rather than improving, or with focal neurologic signs, severe headache, fever or abdominal signs.
- Persistent vomiting with dehydration or electrolyte disturbance (check electrolytes) [1].
- Urinary retention — common early in flight from fluid shifts and anticholinergic drugs [1].
Overview
Space motion sickness (also called space adaptation sickness, SAS) is thought to arise from sensory conflict: without gravity, the otolith organs no longer signal head tilt, mismatching visual and vestibular inputs. A second hypothesis invokes the headward fluid shift [3]. The same conflict happens in reverse after landing (terrestrial readaptation motion sickness) [1][3].
Incidence: 60–80% of space travelers in the first 2–3 days and a similar proportion after return [3]; NASA’s brief cites up to 73% in the first days of an initial flight, and 70–90% overall [1]. Symptoms are worse in first flyers; age, sex and career status show no statistically significant differences [1].
Associated early-flight complaints: headache and facial puffiness/nasal congestion from fluid shift, and space adaptation back pain — 52% of 728 astronauts, mostly mild, with fetal positioning (91%) and analgesics/exercise (85%) the most effective treatments [4].
Medication notes
| Drug | Notes from NASA experience |
|---|---|
| Promethazine | Treatment of choice; untreated crew typically take 72–96 h to resolve, versus relief within 1–2 h after IM or rectal promethazine in Shuttle data [2]; oral, IM, IV and suppository routes all used. Up to 90% initial response. Terrestrial dose 25–50 mg; weight-based dosing under study. Sedation not commonly seen in the first days of flight; stimulants (dextroamphetamine) have been paired to offset sedation [1] |
| Meclizine, cyclizine, dimenhydrinate | Flown historically; anticholinergic/antihistamine sedation risk on Earth [1] |
| Ondansetron | Flown historically [1] |
| Scopolamine | Used historically (incl. scopolamine-dextroamphetamine); no longer available per NASA [1] |
| Prophylaxis before launch | NASA data: no significant difference in symptoms between crew who pretreated (meclizine, scopolamine, promethazine) and those who did not [1]. Shuttle-era scopolamine-dextroamphetamine prophylaxis delayed or failed to prevent symptoms, and NASA moved to treating after symptoms develop [2] |
Mission-type differences
| Mission | Notes |
|---|---|
| Parabolic / suborbital | Seconds to minutes of weightlessness; motion sickness common in parabolic flight; suborbital exposure is brief |
| LEO short | Symptoms span a large share of a short mission; landing readaptation follows within days |
| LEO long | Adaptation in days; readaptation after landing can take weeks [5] |
| Lunar / Mars | Further gravity transitions (0 g ↔ partial g) with no ground team on arrival; scheduling must allow adaptation [1] |
Terrestrial parallels
- Seasickness and car sickness — same sensory-conflict model; the “mal de débarquement” feeling after a long sea voyage resembles readaptation.
- Vestibular neuritis / post-concussion dizziness rehabilitation — the gaze-stabilization and habituation exercises used in vestibular physiotherapy apply to postflight recovery.
Gaps
- No validated predictor of who will be affected [1].
- Optimal, non-sedating prophylaxis is unknown; weight-based promethazine dosing is under study [1].
- Partial-gravity transitions (Moon, Mars) are largely unstudied.
Deeper dive: why promethazine is not as sedating in early flight
Promethazine is an H1 antagonist and weak dopamine (D2) antagonist that acts at the chemoreceptor trigger zone. On Earth it is notably sedating, but NASA reports that it does not appear sedating or associated with operational decrements in the first days of spaceflight [1]. The reason is not established; altered pharmacokinetics in flight, high arousal and stimulant co-administration are possible contributors. See Space pharmacology.
Commercial spaceflight notes
Short orbital flights put most of the mission inside the 2–3-day symptomatic window, so a medication plan matters more for commercial passengers than for career astronauts on long missions. Ensure the participant knows how to self-administer, and that the operator’s flight surgeon has reviewed interactions.
Clinical pearls
- Vomiting on day 1 in orbit is normal; vomiting on day 5 is not — look for another cause.
- After landing, treat the vestibular system and the circulation together: nausea plus orthostatic hypotension is the classic first-day picture.
Evidence profile
- Overall certainty
- ◆◆◆◇ Moderate (proposed)
- Evidence types
- F · Flight dataE · Expert / operational / standards
- Literature through
- 2026-10-14
NASA-STD-3001 requirements referenced 5
| Requirement | Title | Plain-language meaning |
|---|---|---|
| [V1 3003] | In-Mission Preventive Health Care | Includes preventive care for expected adaptation problems. |
| [V1 3004] | In-Mission Medical Care | Treatment capability for in-flight conditions; space adaptation sickness is on NASA's planning list. |
| [V1 4005]–[V1 4010] | Sensorimotor Standards | Sensorimotor function must be maintained for critical tasks, with countermeasures and readaptation. |
| [V1 6006] | EVA Medical Clearance | Crew must be medically cleared before each EVA — vomiting in a suit is dangerous. |
| [V2 7043] | Medical Capability | The medical system must provide the drugs and supplies to treat expected conditions. |
IDs as published in NASA-STD-3001 Vol. 1 Rev C (2023-09-15) and NASA-STD-3001 Vol. 2 Rev F (2026-07-14). NASA-STD-3001 binds NASA programs; it is not a regulation for commercial flights. Paraphrased; read the standard for exact wording. Standards quick reference.
References 7
- NASA OCHMO. Space Adaptation Sickness (SAS). Medical Technical Brief OCHMO-MTB-004 (2025). www.nasa.gov/wp-content/uploads/2025/09/ochmo-mtb-004-space-… NASA E
- Davis JR, Jennings RT, Beck BG. Comparison of treatment strategies for space motion sickness. Acta Astronaut. 1993;29(8):587-591. doi:10.1016/0094-5765(93)90074-7 PMID:11541638 Peer-reviewed F
- Heer M, Paloski WH. Space motion sickness: incidence, etiology, and countermeasures. Auton Neurosci. 2006;129(1-2):77-79. doi:10.1016/j.autneu.2006.07.014 PMID:16935570 Peer-reviewed E
- Kerstman EL, Scheuring RA, Barnes MG, DeKorse TB, Saile LG. Space adaptation back pain: a retrospective study. Aviat Space Environ Med. 2012;83(1):2-7. doi:10.3357/asem.2876.2012 PMID:22272509 Peer-reviewed F
- Mulavara AP, Feiveson AH, Fiedler J, et al. Locomotor function after long-duration space flight: effects and motor learning during recovery. Exp Brain Res. 2010;202(3):649-659. doi:10.1007/s00221-010-2171-0 PMID:20135100 Peer-reviewed F
- NASA OCHMO. Crew Medical Support for Entry, Descent, and Landing. Technical Brief OCHMO-TB-051 (2026). www.nasa.gov/wp-content/uploads/2026/05/ochmo-tb-051-crew-me… NASA E
- NASA OCHMO. Sensorimotor. Technical Brief OCHMO-TB-010. www.nasa.gov/wp-content/uploads/2023/12/ochmo-tb-010-sensori… NASA E
Links and DOI metadata were machine-checked on 2026-10-14 (URL resolves; DOI title/journal/year matched via Crossref). Human verification of each cited claim against its source is still required before review. NASA documents are U.S. Government works (public domain) and are summarized with attribution; journal articles are summarized, not reproduced.
Article info
- Authors
- Pending (AI-assisted draft)
- Reviewer
- Pending review
- Last reviewed
- Pending review
- Literature through
- 2026-10-14
- AI-assisted
- Yes (disclosed)
- COI
- Pending
- License
- CC BY-SA 4.0
- Use
- Educational only · Disclaimer
- Cite this version
- Pending first edition